• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三维质谱成像技术在 TKI 中的应用。

Application of 3D Mass Spectrometry Imaging to TKIs.

机构信息

Department of Oncology, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

Department of Environmental Health Sciences, Mass Spectrometry Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

出版信息

Clin Pharmacol Ther. 2017 Nov;102(5):748-751. doi: 10.1002/cpt.786.

DOI:10.1002/cpt.786
PMID:29023728
Abstract

Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high-performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.

摘要

质谱成像(MSI)允许根据其分子质量可视化组织切片中的内源性和外源性化合物。与高效液相色谱法相比,MSI 的 3D 重建提供了对肿瘤药物分布的更具信息量的描述,突出了肿瘤内药物浓度的异质性。这种附加信息对于理解针对药物的化学抗性可能很重要。在这里,我们在耐药性恶性胸膜间皮瘤的异种移植模型中展示了酪氨酸激酶抑制剂(TKI)伊马替尼的 3D 可视化。

相似文献

1
Application of 3D Mass Spectrometry Imaging to TKIs.三维质谱成像技术在 TKI 中的应用。
Clin Pharmacol Ther. 2017 Nov;102(5):748-751. doi: 10.1002/cpt.786.
2
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.3D 质谱断层成像揭示肿瘤中药物分布的高度异质性。
Sci Rep. 2016 Nov 14;6:37027. doi: 10.1038/srep37027.
3
Drug compound characterization by mass spectrometry imaging in cancer tissue.利用质谱成像技术对癌症组织中的药物化合物进行特征分析。
Arch Pharm Res. 2015 Sep;38(9):1718-27. doi: 10.1007/s12272-015-0627-2. Epub 2015 Jul 23.
4
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.新型酪氨酸激酶抑制剂S116836对表达伊马替尼耐药的FIP1L1-PDGFRα细胞的抗肿瘤活性。
Oncotarget. 2014 Nov 15;5(21):10407-20. doi: 10.18632/oncotarget.2090.
5
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.受体酪氨酸激酶抑制剂和细胞毒性药物对胸膜间皮瘤细胞增殖的影响:以 EGFR 和 ERK1/2 为抗肿瘤靶点的见解。
Biochem Pharmacol. 2011 Nov 15;82(10):1467-77. doi: 10.1016/j.bcp.2011.07.073. Epub 2011 Jul 20.
6
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.SU6668,一种多靶点酪氨酸激酶抑制剂,在原位模型中抑制人恶性胸膜间皮瘤的进展。
Respirology. 2012 Aug;17(6):984-90. doi: 10.1111/j.1440-1843.2012.02193.x.
7
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.酪氨酸激酶抑制剂伊马替尼、厄洛替尼和舒尼替尼在常规临床门诊癌症护理中的血浆浓度。
Ther Drug Monit. 2014 Jun;36(3):326-34. doi: 10.1097/FTD.0000000000000004.
8
2D and 3D MALDI-imaging: conceptual strategies for visualization and data mining.二维和三维基质辅助激光解吸电离成像:可视化与数据挖掘的概念策略
Biochim Biophys Acta. 2014 Jan;1844(1 Pt A):117-37. doi: 10.1016/j.bbapap.2013.01.040. Epub 2013 Mar 4.
9
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.索拉非尼和依维莫司联合用药在恶性胸膜间皮瘤的临床前模型中显示出抗肿瘤活性。
BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1.
10
Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.简短报告:伊马替尼对一名血小板衍生生长因子受体阳性的胸膜恶性孤立性纤维性肿瘤患者的疗效
J Thorac Oncol. 2008 Aug;3(8):938-41. doi: 10.1097/JTO.0b013e3181803f08.

引用本文的文献

1
Advances in mass spectrometry imaging for spatial cancer metabolomics.质谱成像技术在空间癌症代谢组学中的进展。
Mass Spectrom Rev. 2024 Mar-Apr;43(2):235-268. doi: 10.1002/mas.21804. Epub 2022 Sep 6.
2
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.聚乙二醇化重组人透明质酸酶(PEGPH20)预处理可改善紫杉醇在临床前模型中的肿瘤内分布和疗效。
J Exp Clin Cancer Res. 2021 Sep 10;40(1):286. doi: 10.1186/s13046-021-02070-x.
3
Experimental and Data Analysis Considerations for Three-Dimensional Mass Spectrometry Imaging in Biomedical Research.
实验和数据分析在生物医学研究中三维质谱成像的考虑因素。
Mol Imaging Biol. 2021 Apr;23(2):149-159. doi: 10.1007/s11307-020-01541-5. Epub 2020 Oct 6.
4
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging.质谱成像定量测定尼拉帕利和奥拉帕利的肿瘤分布。
Int J Biol Sci. 2020 Feb 21;16(8):1363-1375. doi: 10.7150/ijbs.41395. eCollection 2020.
5
Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors.定量质谱成像揭示胃肠道间质瘤肝转移中存在伊马替尼耐药与突变状态无关。
Sci Rep. 2019 Jul 23;9(1):10698. doi: 10.1038/s41598-019-47089-5.
6
Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist.质谱组织成像:药物化学家实用指南
ACS Med Chem Lett. 2019 Jan 11;10(2):161-167. doi: 10.1021/acsmedchemlett.8b00480. eCollection 2019 Feb 14.
7
Mass Spectrometry Imaging: A Review of Emerging Advancements and Future Insights.质谱成像:新兴进展与未来展望综述
Anal Chem. 2018 Jan 2;90(1):240-265. doi: 10.1021/acs.analchem.7b04733. Epub 2017 Dec 13.
8
Kinase Inhibitors: The Reality Behind the Success.激酶抑制剂:成功背后的现实
Clin Pharmacol Ther. 2017 Nov;102(5):726-730. doi: 10.1002/cpt.815.